{
    "nct_id": "NCT05623501",
    "official_title": "Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease",
    "inclusion_criteria": "* No prior medical history of alcohol use disorder or alcohol-associated liver disease\n* Between 18-60 years old\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 60 Years",
    "exclusion_criteria": "* Weight below 50kg.\n* Advanced liver disease\n* Other acute liver diseases\n* HIV co-infection\n* History of pancreatic or biliary disease\n* Acute illness that would interfere with drug absorption\n* Pregnancy\n* Participants who are currently taking drugs with CYP3A4 effects\n* FIB-4 Index > 1.30\n* History of Alcohol Use Disorder (AUD) determined by score > 8 on AUDIT questionnaire",
    "miscellaneous_criteria": ""
}